Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 5004Neoplasms 4197Prostatic Neoplasms 2428Carcinoma, Non-Small-Cell Lung 2265Colorectal Neoplasms 2053Lung Neoplasms 1705Multiple Myeloma 1459Lymphoma 1405Leukemia, Myeloid, Acute 1382Neoplasm Metastasis 1374Melanoma 1270Pancreatic Neoplasms 1200Leukemia 1196Ovarian Neoplasms 1192Lymphoma, Non-Hodgkin 1132Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091Head and Neck Neoplasms 1056Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 897Colonic Neoplasms 895Brain Neoplasms 876Stomach Neoplasms 857Recurrence 853Carcinoma, Hepatocellular 846Glioblastoma 841Lymphoma, Large B-Cell, Diffuse 771Rectal Neoplasms 759Uterine Cervical Neoplasms 728Carcinoma, Renal Cell 705Hodgkin Disease 698

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Interventional × Translocation, Genetic × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡